- Home
- OPFI vs LRMR Comparison
OPFI vs LRMR Comparison
Compare OPFI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- LRMR
- Stock Information
- Founded
- OPFI 2009
- LRMR N/A
- Country
- OPFI United States
- LRMR United States
- Employees
- OPFI N/A
- LRMR N/A
- Industry
- OPFI Finance: Consumer Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- LRMR Health Care
- Exchange
- OPFI Nasdaq
- LRMR Nasdaq
- Market Cap
- OPFI 288.7M
- LRMR 332.1M
- IPO Year
- OPFI N/A
- LRMR N/A
- Fundamental
- Price
- OPFI $9.94
- LRMR $3.22
- Analyst Decision
- OPFI Buy
- LRMR Strong Buy
- Analyst Count
- OPFI 2
- LRMR 7
- Target Price
- OPFI $11.75
- LRMR $16.71
- AVG Volume (30 Days)
- OPFI 840.3K
- LRMR 1.8M
- Earning Date
- OPFI 10-29-2025
- LRMR 11-14-2025
- Dividend Yield
- OPFI 2.58%
- LRMR N/A
- EPS Growth
- OPFI N/A
- LRMR N/A
- EPS
- OPFI 0.14
- LRMR N/A
- Revenue
- OPFI $335,437,000.00
- LRMR N/A
- Revenue This Year
- OPFI $119.75
- LRMR N/A
- Revenue Next Year
- OPFI $10.98
- LRMR N/A
- P/E Ratio
- OPFI $71.62
- LRMR N/A
- Revenue Growth
- OPFI 28.69
- LRMR N/A
- 52 Week Low
- OPFI $4.83
- LRMR $1.61
- 52 Week High
- OPFI $17.73
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- OPFI 44.49
- LRMR 35.01
- Support Level
- OPFI $9.00
- LRMR $3.87
- Resistance Level
- OPFI $10.33
- LRMR $4.50
- Average True Range (ATR)
- OPFI 0.51
- LRMR 0.28
- MACD
- OPFI 0.02
- LRMR -0.09
- Stochastic Oscillator
- OPFI 34.45
- LRMR 6.63
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.